Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Hexasiil
- Development stage
- Unknown
- Lead developer
- Serum Institute of India
- Modality
- Vaccines & Immunotherapeutics
- Administration
- Intramuscular
01
Overview
Hexasiil is a fully liquid hexavalent combination vaccine developed by the Serum Institute of India (SIIPL). It is designed to provide active immunization against six major childhood diseases: diphtheria, tetanus, pertussis (whooping cough), hepatitis B, poliomyelitis, and invasive infections caused by Haemophilus influenzae type b (Hib). The vaccine is a DTwP-HepB-IPV-Hib formulation, containing diphtheria and tetanus toxoids, whole-cell pertussis (wP), recombinant hepatitis B surface antigen (HepB), inactivated poliovirus (IPV) types 1, 2, and 3, and Hib conjugate. Hexasiil is notable for being the first WHO-prequalified fully liquid hexavalent vaccine that incorporates whole-cell pertussis, allowing for easier administration in a single injection. It is typically administered as a three-dose primary series in infants at 6, 10, and 14 weeks of age.
- Brand names
- Hexasiil
- Other names
- DTwP-HepB-IPV-Hib vaccineSIIPL hexavalent vaccine
02
Targets
Poliovirus type 1 D-antigenHBsAg (Hepatitis B surface antigen)Poliovirus type 3 D-antigenTT (Tetanus toxoid)
Beyond the preview
Go deeper on Hexasiil.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Hexasiil.